Table 4 Univariate and multivariate Cox regression analysis for the prediction of the primary combined endpoint

Sex, male (n,%)

0.832(0.589–1.933)

0.832

Age (years)

1.017(0.994–1.039)

0.147

Arterial hypertension (n,%)

1.171(0.655–2.091)

0.595

Dyslipidemia (n,%)

1.302(0.751–2.258)

0.347

Diabetes mellitus (n,%)

1.793(1.024–3.139)

0.041

Smoker (n,%)

1.391(0.776–2.493)

0.268

NYHA functional class III-IV/IV

2.077(1.508–2.863)

<  0.001

Previous coronary artery disease (n,%)

1.698(0.907–3.180)

0.098

Ischemic vs non-ischemic cardiomyopathy (n,%)

2.226(1.248–3.970)

0.007

Atrial fibrillation (n,%)

1.337(0.737–2.427)

0.339

Stage 3–4 renal failure (eGFR< 50 ml/min/1.73m²)

2.224(0.898–5.509)

0.084

Sodium (mEq/L)

0.933(0.852–1.021)

0.131

NT-proBNP (pg/mL)

0.997(0.891–1.011)

0.880

LVEF (%)

0.994(0.965–1.025)

0.711

TAPSE (mm)

0.963(0.886–1.046)

0.370

SPAP (mmHg)

1.014(0.991–1.038)

0.243

TAPSE/SPAP (mm/mmHg)

0.163(0.015–1.791)

0.138

LVEF (%)

0.984(0.957–1.012)

0.265

RVEF (%)

1.007(0.989–1.025)

0.448

LGE presence (n,%)

1.310(0.715–2.398)

0.382

LGE ischemic-pattern (n, %)

1.994(1.036–3.840)

0.039

LGE non-ischemic pattern(n,%)

0.598(0.314–1.139)

0.118

MvPA ≤9 cm/s

2.557(1.459–4.482)

0.001

CMR – PVR (WU)

1.132(1.007–1.272)

0.038

Minimal PA-area (cm2)

1.215(1.043–1.415)

0.012

Maximal PA-area (cm2)

1.180(1.032–1.350)

0.016

PA pulsatility (%)

0.220(0.035–1.382)

0.106

Emax/Ea

1.120(0.716–1.753)

0.620

Variable

HR (95% CI)

P-Value

Diabetes mellitus (n,%)

1.261(0.775–2.051)

0.351

NYHA functional class III-IV/IV

2.957(1.841–4.750)

< 0.001

Stage 3–4 renal failure (eGFR< 50 ml/min/1.73m²)

2.113(1.144–3.904)

0.017

Ischemic vs non-ischemic cardiomyopathy (n,%)

1.737(1.072–2.816)

0.025

MvPA ≤9 cm/s

1.782(1.105–2.874)

0.018